BIOPHYTIS S.A.

NASDAQ: BPTSY (Biophytis SA)

Kemas kini terakhir: 05 Jul, 4:03AM

1.45

0.00 (0.00%)

Penutupan Terdahulu 1.45
Buka 1.45
Purata Dagangan (3B) 49
Modal Pasaran 3,416,345
Harga / Buku (P/B) 2.26
Julat 52 Minggu
1.38 (-4%) — 7.48 (415%)
Tarikh Pendapatan 4 Jun 2025 - 10 Jun 2025
EPS Cair (TTM) -16.55
Nisbah Semasa (MRQ) 0.410
Aliran Tunai Operasi (OCF TTM) -10.66 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -4.51 M
Pulangan Atas Aset (ROA TTM) -65.37%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok Biophytis SA - -

AISkor Stockmoo

0.0
Konsensus Penganalisis 0.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 0.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BPTSY 3 M - - 2.26
LEGN 7 B - - 7.75
IMCR 2 B - - 4.69
JBIO 305 M - - -
OKUR 31 M - - 0.370
QTTB 27 M - - 3.55

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Institusi 0.04%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
22 Apr 2025 Pengumuman Biophytis Targets Mobility Restoration in Patients with Obesity
1.481.481.431.431.371.371.321.321.261.26Jul 3Jul 3Jul 7Jul 7Jul 8Jul 8Jul 9Jul 9Jul 10Jul 10Jul 11Jul 11Jul 14Jul 14Jul 15Jul 15

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0500.050-0.000-0.000-0.050-0.050-0.100-0.100-0.150-0.150MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda